PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

BACKGROUND: Anti-programmed cell death protein 1 and programmed cell death ligand 1 (PD-L1) agents are broadly used in first-line and second-line treatment across different tumor types. While immunohistochemistry-based assays are routinely used to assess PD-L1 expression, their clinical utility rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldelli, Elisa, Hodge, K Alex, Bellezza, Guido, Shah, Neil J, Gambara, Guido, Sidoni, Angelo, Mandarano, Martina, Ruhunusiri, Chamodya, Dunetz, Bryant, Abu-Khalaf, Maysa, Wulfkuhle, Julia, Gallagher, Rosa I, Liotta, Lance, de Bono, Johann, Mehra, Niven, Riisnaes, Ruth, Ravaggi, Antonella, Odicino, Franco, Sereni, Maria Isabella, Blackburn, Matthew, Zupa, Angela, Improta, Giuseppina, Demsko, Perry, Crino', Lucio, Ludovini, Vienna, Giaccone, Giuseppe, Petricoin, Emanuel F, Pierobon, Mariaelena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499669/
https://www.ncbi.nlm.nih.gov/pubmed/34620701
http://dx.doi.org/10.1136/jitc-2020-002179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499669/
https://www.ncbi.nlm.nih.gov/pubmed/34620701
http://dx.doi.org/10.1136/jitc-2020-002179

Ejemplares similares